The global intravenous (IV) fluid bags market is projected to grow at a compound annual growth rate (CAGR) of approximately 6 ...

IV iron administration has historically been a “controversial issue” for treatment of iron deficiency anemia during acute ...

First-in-class ianalumab in second-line setting led to sustained disease control ...

DelveInsight's Acute on Chronic Liver Failure Market Insights report includes a comprehensive understanding of current ...

Discusses Clinical Progress of Lead Drug Candidates Targeting Parkinson's, Alzheimer's, and Liver Disease December 9, 2025 4:15 ...

Quetzal Therapeutics, a biopharmaceutical company specializing in developing transformative treatments for rare diseases, announced the initiation of a pivotal Phase III clinical trial of QTX-2101, an ...

Azacitidine plus venetoclax significantly improved multiple outcomes for certain patients with acute myeloid leukemia ...

The medical center earned 2026 High Performing hospital for Maternity Care recognition, the highest award a hospital can earn ...

Pfizer presents positive results from phase 3 BASIS study of Hympavzi in adults and adolescents with haemophilia A or B with inhibitors at ASH meeting: New York Tuesday, December ...

New Investigator Sponsored Data Suggest Trilaciclib May Mitigate Chemotherapy-Induced TP53-Mutant Clonal Hematopoiesis. EINPresswire/ -- Pharmacosmos Therapeutics Inc. today announced the presentation ...

Ianalumab (9 mg/kg) plus eltrombopag extended ITP disease control by 45% with patients maintaining disease control 2.8 times longer than with placebo plus eltrombopag1,262% of patients treated with ...

Cynata reports encouraging results from the first cohort of its phase 1/2 NEREID kidney transplant trial, with no safety ...